...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Answers from IR
11
Jun 07, 2018 11:05PM
3
Jun 07, 2018 11:32PM
1
Jun 08, 2018 12:41AM
6
Jun 08, 2018 01:49AM

This could be extremely good news for not only the CVD part of the trial but the secondary indications as well. I'm very jazzed to hear about the extension of the dosing.

tada

3
Jun 08, 2018 09:30AM
Share
New Message
Please login to post a reply